Ebola infections in the Democratic Republic of Congo are declining, but public health officials caution that the virus may be hiding in remote communities. The World Health Organization reported 42 new cases last week, down from 56 the week before, yet the situation remains volatile. 'We are cautiously optimistic, but we cannot ignore the possibility of a hidden surge,' said Dr. Alhaji Sow, incident manager for the WHO Ebola response. The disease has killed more than 600 people since July, making it the second deadliest Ebola outbreak in history.
British scientists are at the forefront of vaccine development. The University of Oxford, in collaboration with Johnson & Johnson, is conducting a phase 2 trial of a two-dose Ebola vaccine regimen. The trial involves 1,500 volunteers in the UK and Sierra Leone, and preliminary results are expected by March. 'This vaccine could be a game-changer,' said Professor Sarah Gilbert, lead researcher on the project. 'Unlike the current single-dose vaccine, which requires ultra-cold storage, our two-dose regimen can be stored at standard refrigerator temperatures, making it easier to deploy in remote areas.'
The need for effective vaccines is urgent. The current Ebola outbreak is affecting regions with poor infrastructure and active conflict zones, complicating containment efforts. 'The virus is exploiting the cracks in the system,' said Dr. Michael Ryan, executive director of the WHO Health Emergencies Programme. 'We are seeing cases in areas where we cannot reach, and that is deeply concerning.'
The British government has pledged £50 million to support the vaccine trials and strengthen local health systems. 'This is a global health emergency that requires a collective response,' said International Development Secretary Penny Mordaunt. 'British innovation is leading the fight against Ebola, and we will not rest until the outbreak is contained.'
Critics argue that more funding should be directed toward community engagement and contact tracing, rather than vaccine development. 'Vaccines are important, but they are not a silver bullet,' said Dr. Joanne Liu, international president of Médecins Sans Frontières. 'We need to build trust with affected communities and ensure that people are informed about the risks and prevention measures.'
The WHO is also exploring the use of experimental therapies, including monoclonal antibodies and antiviral drugs. 'We are in a better position than ever before to combat Ebola,' said Dr. Tedros Adhanom Ghebreyesus, WHO director-general. 'But we must remain vigilant and ensure that our response is agile and adaptable to the changing dynamics of the outbreak.'
As the world watches the numbers, the silent worry is that the true scope of the outbreak may be underestimated. 'Every case we miss is a potential death sentence for that person and a transmission risk for others,' said Dr. Sow. 'We are in a race against time, and we cannot afford to slow down.'
